MedTrace Logo

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

NCT00243646 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2016-04-14

No results posted yet for this study

Summary

Determine the role of androgen deprivation therapy in high risk patients receiving 45 Gy of pelvic radiotherapy plus a Pd-103 boost and the impact of the duration of ADT in hormonally-manipulated patients.

Conditions

Interventions

RADIATION

External beam radiation

All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant

DRUG

Lupron

9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).

DRUG

Casodex

9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).

Sponsors & Collaborators

  • Kent E. Wallner, M.D.

    collaborator UNKNOWN

  • Sylvester, John, M.D.

    collaborator INDIV

  • Schiffler Cancer Center

    lead OTHER

Principal Investigators

  • Gregory S Merrick, MD · Schiffler Cancer Center, Wheeling, WV

  • Kent E. Wallner, MD · Group Health Cooperative, Veterans Administration Hospital, and University of Washington

  • John Sylvester, MD · Seattle Prostate Institute Seattle, WA 98104

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243646 on ClinicalTrials.gov